The UK is Restarting a Puberty Blocker Trial Despite 25 Years of Evidence - Carrie Clark (#4)
When the NHS announced a new puberty blocker research programme, many assumed the Cass Review had changed things. Carrie Clark, Director of Genspect UK, joins Stella O'Malley and Mia Hughes to show why that hope was premature. Ireland has watched the UK's gender medicine reckoning with close interest, and this episode matters here because the same ideological pressures, the same clinical frameworks, and the same reluctance to follow inconvenient evidence operate on both sides of the Irish Sea.
When the Cass Review delivered its landmark findings on the Tavistock clinic, there was a reasonable expectation that a period of honest reflection would follow in UK gender medicine. That expectation has not been met. The NHS is now proposing the Pathways study, a £10 million research programme into puberty blockers, and Carrie Clark, Director of Genspect UK, joins Stella O'Malley and Mia Hughes to explain why this new study risks repeating the very mistakes it claims to be investigating. Clark's central concern is that the Pathways study is built on a flawed premise. Rather than beginning from a position of genuine scientific uncertainty, the research framework has been shaped by activist language and gender-identity ideology. There are no exclusion criteria for children with serious mental health conditions or autism, meaning some of the most vulnerable young people could be enrolled without the protections that basic ethical research standards would normally require. For a study positioned as a careful, evidence-based inquiry, this is a serious and revealing omission. The episode also confronts an uncomfortable truth about what the NHS has chosen not to know. Approximately 9,000 children passed through the now-closed Gender Identity Development Service at the Tavistock clinic, yet the NHS has declined to conduct any systematic follow-up on their outcomes. At the same time, Tavistock's own Early Intervention Study, run precisely to generate the evidence base the NHS claims is still lacking, produced results that were quietly set aside rather than published. The pattern is not one of insufficient data. It is one of inconvenient data. Clark also walks through the methodological problems in the Dutch Protocol, the original research that underpins puberty blocker use in gender medicine internationally. The protocol's limitations have been widely noted, yet it continues to function as the foundational justification for a medical pathway that has expanded far beyond the narrow population it originally studied. A major US study with similarly hidden results compounds the picture. The evidence base, in short, is far thinner than advocates for this pathway suggest. For Irish listeners, this episode carries direct relevance. Ireland has been watching the UK's gender medicine crisis with growing attention, and many of the same pressures that shaped Tavistock's culture are not absent here. Irish parents with concerns, Irish clinicians navigating an ideologically charged environment, and Irish policymakers considering how to respond to the Cass Review's implications all need to understand the mechanism by which evidence gets set aside in favour of ideology. Stella O'Malley brings her perspective as an Irish psychotherapist who has worked with gender-questioning young people, grounding the UK-focused conversation in realities that Irish families recognise. The episode ends with a clear call to stop the Pathways study before children are enrolled into research that its architects cannot honestly justify. For Ireland, the lesson extends beyond England's borders. It is about how quickly a medical establishment can convince itself that proceeding in the face of evidence is the same thing as proceeding with caution.
